An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers	Advanced Solid Tumor	Enrolling by invitation	Phase 1	2026-09-21		NCT06169579

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Shenzhen Innovation Center for Small Molecule Drug Discovery Co., Ltd.	1
Shenzhen NewDEL Biotech, Co., Ltd	1
Sun Yat-Sen University Cancer Center	74

21 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center	Shenzhen	China	4
Gansu Provincial Cancer Hospital	Lanzhou	China	4
General Hospital of Ningxia Medical University	Yinchuan	China	24
Guangxi Medical University Cancer Hospital	Nanning	China	24
Hunan Cancer Hospital	Changsha	China	87
Jiangxi Cancer Hospital	Nanchang	China	22
Linyi Cancer Hospital	Linyi	China	22
Shandong Cancer Hospital & Institute	Jinan	China	4
Sichuan Cancer Hospital	Chengdu	China	30
Sir Run Run Shaw Hospital	Hangzhou	China	7
Sun Yat-Sen University Cancer Center	Guangzhou	China	113
the Affiliated Hospital of Guizhou Medical University	Guiyang	China	29
The First Affiliated Hospital Of Xiamen University	Xiamen	China	50
The First Hospital of China Medical University	Shenyang	China	42
The First Hospital of Lanzhou University	Lanzhou	China	26
The Second People's Hospital of Neijiang	Neijiang	China	2
The Sixth Affiliated Hospital of Sun Yat-sen University	Guangzhou	China	9
Tianjin Medical University Cancer Institute & Hospital	Tianjin	China	23
Tongji Hospital Tongji Medical College of HUST	Wu’an	China	1
Yunnan Cancer Hospital	Kunming	China	27
Zhanjiang Central Hospital, Guangdong Medical University	Zhanjiang	China	1

Clinical trials